461 related articles for article (PubMed ID: 30845114)
1. Biomarkers for immune therapy in gastrointestinal cancers.
Weinberg BA; Hameed R; Marshall JL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
[TBL] [Abstract][Full Text] [Related]
2.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
3. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau I
Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
[TBL] [Abstract][Full Text] [Related]
4. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
6. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
8. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
10. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
12. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
13. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
15. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
Chen JA; Ma W; Yuan J; Li T
Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
17. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
